ABCL Q1 2023 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M-96.1% YoY

Gross Profit

$12M100.0% margin

Operating Income

-$65M-532.1% margin

Net Income

-$40M-329.0% margin

EPS (Diluted)

$-0.14

QoQ Revenue Growth

-43.4%

Cash Flow

Operating Cash Flow

-$44M

Free Cash Flow

-$59M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$289M

Stockholders' Equity

$1.2B

Cash & Equivalents

$193M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$317M	-96.1%
Gross Profit	$12M	$272M	-95.5%
Operating Income	-$65M	$225M	-128.8%
Net Income	-$40M	$169M	-123.8%

Revenue Segments

Research Fees

$11M87%

Milestone Payments

$1M10%

License

$372,0003%